
iStock, Alena Butusava
NEW YORK — November 17, 2026 — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced positive topline results today from its pivotal Phase 3 REGAL clinical trial evaluating Galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The study achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to investigator-selected best available therapy (BAT).
Key Clinical Findings
The randomized REGAL trial assessed GPS as a maintenance monotherapy in AML patients who had achieved a second or later complete remission (CR2 or later, including CRp2) following second-line or subsequent salvage therapy, and who were ineligible for or unable to undergo allogeneic stem cell transplantation.
Triggered after reaching the pre-specified 80 survival events (deaths) outlined in the statistical analysis plan, the topline data revealed:
- 41% Reduction in Risk of Death: Patients treated with GPS achieved a hazard ratio (HR) of 0.59 (two-sided p = 0.035) compared to the control arm.
- Extended Median Survival: Median overall survival reached 24.0 months in the GPS cohort, outperforming the 14.7 months observed in patients receiving best available therapy—an absolute survival gain of 9.3 months.
- Favorable Safety Profile: GPS was well tolerated with no new safety signals identified. Treatment-related adverse events were predominantly mild to moderate (Grade 1/2), with localized injection-site reactions being the most common.
“REGAL has achieved its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for AML patients with extremely limited options after achieving a second remission,” said Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS. “The magnitude of survival benefit observed with our investigational GPS vaccine represents a defining milestone for SELLAS and provides Phase 3 validation for our WT1-targeted immunotherapy technology.”
Regulatory Path Forward
Following these results, SELLAS plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated regulatory pathway and advance preparations for a Biologics License Application (BLA) submission, targeted for the first half of 2027. Comprehensive evaluations of secondary endpoints and pre-specified subgroup analyses are currently underway for presentation at an upcoming major medical conference and submission to a peer-reviewed journal.
Industry Context: A Turning Point for Therapeutic Cancer Vaccines
The success of the REGAL trial marks a significant breakthrough not only for relapsed/refractory AML patients, who historically face dismal prognoses when ineligible for stem cell transplants, but also for the broader field of therapeutic cancer vaccines.
Unlike prophylactic vaccines that prevent viral infections linked to cancer (such as HPV or Hepatitis B), therapeutic cancer vaccines are designed to train a patient’s immune system to recognize and eliminate existing malignant cells. For decades, this modality struggled in late-stage clinical trials due to tumor immune evasion and weak antigen immunogenicity. However, recent advancements in antigen selection, adjuvant design, and patient stratification—specifically deploying vaccines in minimal residual disease (MRD) or remission settings rather than against bulky, late-stage tumors—have revitalized the sector.
Galinpepimut-S targets the Wilms Tumor 1 (WT1) protein, an intracellular antigen overexpressed across a wide range of hematologic malignancies and solid tumors, while largely absent in healthy adult tissues. By inducing robust CD4+ and CD8+ T-cell responses against WT1-expressing residual leukemia cells during remission, GPS aims to prevent or delay relapse without the severe systemic toxicity often associated with intensive chemotherapy or cellular therapies. As more vaccine platforms—spanning peptide-based approaches like GPS to personalized mRNA candidates—mature in pivotal trials, therapeutic vaccines are increasingly poised to become a cornerstone of post-remission maintenance oncology.
Specialty calculators
For clinical reference; use professional judgment.